Imunon, Inc. will hold a conference call on May 12, 2026, to report its first quarter financial results and update investors on the clinical development of IMNN-001, its DNA-based immunotherapy for advanced ovarian cancer. The company is advancing Phase 3 trials of IMNN-001, which aims to boost cancer-fighting molecules at tumor sites. This update follows successful Phase 2 trials showing improved survival rates, positioning IMNN-001 as a promising treatment option. Investors can join the call via phone or webcast to learn more about the company’s progress and future plans.
Solaris Energy Infrastructure (SEI) maintains a Buy rating with a new price target of $97, driven by strong growth from its Power Solutions segment and a 2.2GW contracted capacity with major tech clients. Its upcoming inclusion in the S&P SmallCap 60...
XRP Ledger's AI agents have completed over 1 million transactions but with low financial volume, indicating the AI economy is still in early stages. Bitcoin mining veteran Chandler Guo predicts Bitcoin will hit $120,000 within a year and $500,000 in ...
Argan, Inc. reported a strong first quarter for fiscal year 2027 with a 50% increase in revenue, reaching a record $290.9 million. This growth was fueled by multiple project completions and a robust $2.8 billion backlog, supported by rising energy de...
The Global X Russell 2000 Covered Call ETF (RYLD) provides a high monthly yield of 11.9% and achieved a 20.5% total return over the past year. However, its strategy involving at-the-money options causes structural net asset value (NAV) erosion and ca...
A Cambridge study found Ethereum's annual energy consumption at 7.87 gigawatt-hours, making it the second-least energy-intensive proof-of-stake (PoS) blockchain when adjusted for market value. This marks a significant improvement from its previous pr...
